A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaddoura, Rasha, Dabdoob, Wafer A., Ahmed, Khalid, Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286131/
https://www.ncbi.nlm.nih.gov/pubmed/37358999
http://dx.doi.org/10.3389/fmed.2023.1163137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286131/
https://www.ncbi.nlm.nih.gov/pubmed/37358999
http://dx.doi.org/10.3389/fmed.2023.1163137

Ejemplares similares